Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Moves to give biosimilars nonproprietary names different from brand products are more than a wrangle about words—they could mean biosimilars arrive stillborn to the market.
Improving the integration of computational analysis into biology will require better documentation, validation and accessibility of software associated with papers.
An international alliance to enable secure sharing of human genomic and clinical data merits both broad support and financial backing from the global research and clinical communities.
To prevent a popular backlash against the spiraling prices of US prescription medicines, industry needs to do more to address out-of-pocket expenses for patients.
Increasing public and private sector cooperation to support long-term, longitudinal population studies is critical to advance translational research on complex diseases.
Despite their limitations, in vitro assays are a simple means for assessing the drug sensitivity of a patient's cancer. After consulting experts in the community, we think such assays deserve a second look.
A slew of disappointing product launches suggests biotech companies are ill prepared to navigate an increasingly parsimonious reimbursement environment.